Safety and Immunogenicity of an Adjuvanted Chikungunya Virus (CHIKV) Virus-like Particle (VLP) Based Vaccine in Two Pivotal Phase 3 Trials, ≥12 Years of Age

Authors
Category Primary study
ConferenceOpen Forum Infectious Diseases
Year 2023
This article has no abstract
Epistemonikos ID: 08a44a69d9e704dc4b6e22634e54213c3917c80c
First added on: Feb 17, 2025